HS-10510

HS-10510 is a **novel small molecule oral drug** in development for the treatment of **primary hypercholesterolaemia and dyslipidaemias**. The drug is being developed by **Jiangsu Hansoh Pharmaceutical**. Although its **mechanism of action is officially listed as undefined**, some sources classify it as a **PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor**, a class known for lowering LDL cholesterol. As of July 2025, HS-10510 has not yet entered human trials but has received clinical trial approval in China and is anticipated to begin Phase 1 studies soon for dyslipidaemias and hypercholesterolaemia. It is considered a new molecular entity and is not a combination drug nor a biosimilar or generic. Its route of administration is oral (tablet)[1][7][8][10].